References
- The American Academy of Pain Medicine. AAPM Facts and Figures on Pain. 2013. Available at: http://www.painmed.org/patientcenter/facts_on_pain.aspx [Last accessed 11 April 2013]
- Institute of Medicine Report from the Committee on Advancing Pain Research. Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. Washington, DC: The National Academies Press, 2011
- Johannes CB, Le TK, Zhou X, et al. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010;11:1230-9
- American Pain Foundation. Voices of Chronic Pain: A National Study Conducted for American Pain Foundation. New York, NY: David Michaelson & Company; 2006
- Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895-926
- Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51
- Berry PH, Chapman CR, Covington EC, et al. Pain: Current Understanding of Assessment, Management, and Treatments. Reston, VA: National Pharmaceutical Council Inc. and the Joint Commission on Accreditation of Healthcare Organizations, 2001
- Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. The J Am Board Fam Pract 2001;14:211-18
- The British Pain Society. Opioids for Persistent Pain: Good Practice. London, WC: The British Pain Society, 2010
- American Pain Society in Conjunction with The American Academy of Pain Medicine. Guideline for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain: Evidence Review. Chicago, IL: American Pain Society; 2009
- Kahan M, Mailis-Gagnon A, et al. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Can Fam Physician 2011;57:1257-66, e407-18
- Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Washington, DC: Department of Veterans Affairs, Department of Defense; 2010
- Washington State Agency Medical Directors' Group. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid treatment. Olympia, WA: Washington State Department of Labor and Industries; 2010
- Ambrosio F, Finco G, Mattia C, et al. SIAARTI recommendations for chronic noncancer pain. Minerva Anestesiologica 2006;72:859-80
- Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiologica 2005;71:425-33
- Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain: Part 2 – Guidance. Pain Physician 2012;15(3 Suppl):S67-116
- Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
- Purdue Pharma. BTDS (buprenorphine) Transdermal System – Full Prescribing Information. 2012
- Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scand J Pain 2010;1:122-41
- Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Therapeut 2010;32:844-60
- Gordon A, Rashiq S, Moulin DE, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag 2010;15:169-78
- James IGV, O'Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manag 2010;40:266-78
- Landau CJ, Carr WD, Razzetti AJ, et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Therapeut 2007;29:2179-93
- Karlsson M, Berggren A-C. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Therapeut 2009;31:503-13
- Guetti C, Angeletti C, Marinangeli F, et al. Transdermal buprenorphine for central neuropathic pain: clinical reports. Pain Practice 2011;11:446-52
- Steiner D, Munera C, Hale M, et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain 2011;12:1163-73
- Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 2011;42:903-17
- Pergolizzi JV, Ben-Joseph R, Chang CL, Hess G. Predicting medication persistence to buprenorphine transdermal system. Pain Practice 2014 [Epub ahead of print]
- Cass LJ. Pentazocine vs morphine. JAMA 1964;189:332
- Janssen Pharmaceuticals. Duragesic (Fentanyl Transdermal System) – Full Prescribing Information. 2012
- Smith HS. Opioid Therapy in the 21st Century. New York, NY: Oxford University Press, Inc., 2008
- Utah Department of Health. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. Salt Lake City, Utah: Utah Department of Health, 2009
- Kobus AM, Smith DHM, Morasco BJ, et al. Correlates of higher-dose opioid medication use for low back pain in primary care. J Pain 2012;13:1131-8
- Duensing L, Eksterowicz N, Macario A, et al. Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids. Curr Med Res Opin 2010;26:1579-85
- New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. Available from: http://www.nehi.net/publications/17-thinking-outside-the-pillbox-a-system-wide-approach-to-improving-patient-medication-adherence-for-chronic-disease/view. [Last accessed 22 March 2014]
- Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract 2003;133:9-14; discussion 23-4
- Bohme K. Buprenorphine in a transdermal therapeutic system – a new option. Clin Rheumatol 2002;21(Suppl 1):S13-16